Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1273 • ACR Convergence 2022
Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: Data Availability and Preliminary Measure Performance in the RISE Registry
April Jorge¹, Alfredo Aguirre², April Barnado³, Bonnie Bermas⁴, Candace Feldman⁵, Shraddha Jatwani⁶, Alex Limanni⁷, JoAnn Zell⁸, Claire Barber⁹, Ali Duarte-Garcia¹⁰, Shivani Garg¹¹, Jing Li², Gabriela Schmajuk¹², Jinoos Yazdany¹³ and Christie Bartels¹⁴, ¹Massachusetts General Hospital, Boston, MA, ²University of California, San Francisco, San Francisco, CA, ³Vanderbilt University Medical Center, Nashville, TN, ⁴UT Southwestern, Dallas, TX, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Albert Einstein Medical Center, Ambler, PA, ⁷Self, Dallas, TX, ⁸University of Colorado Anschutz Medical Campus, Denver, CO, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Mayo Clinic, Rochester, MN, ¹¹University of Madison, School of Medicine and Public Health, Madison, WI, ¹²UCSF / SFVA, San Francisco, CA, ¹³UCSF, San Francisco, CA, ¹⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Digital quality measures can facilitate monitoring and improvement of health care quality on a population level. As part of a CDC-funded ACR initiative to…
Abstract Number: 1374 • ACR Convergence 2022
Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study
Jordan Roberts¹, Mindy Lo¹, Rebecca Sadun², Emily Smitherman³, Scott Wenderfer⁴ and Mary Beth F. Son¹, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Duke University, Durham, NC, ³University of Alabama at Birmingham, Birmingham, AL, ⁴British Columbia Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Belimumab is the only targeted therapy approved for pediatric systemic lupus erythematosus (pSLE), although use remains limited in children. While clinical trials and studies…
Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
Abstract Number: 1468 • ACR Convergence 2022
Apathy Measurement in a Cohort of Systemic Lupus Erythematosus
Mike Putman¹, David Gazeley² and Ikechukwu Mbonu³, ¹The Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Up to 40% of patients with systemic lupus erythematosus (SLE) have measurable cognitive dysfunction on neuropsychiatric testing. Around 83% of patients are nonadherent with…
Abstract Number: 1538 • ACR Convergence 2022
Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
Aya abugharbyeh, Sadik Khuder and bashar Kahaleh, University of Toledo, Toledo, OH
Background/Purpose: Evidence suggest that autoimmune diseases tend to coexist at a higher rate than expected, reflecting a common pathogenetic pathway. However, data sets have shown…
Abstract Number: 1692 • ACR Convergence 2022
Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
Shannon Estadt, Mehrnaz Gharaee-Kermani, Bin Xu, Tyson Moore, Andrew Hannoudi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by enhanced sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease…
Abstract Number: 1726 • ACR Convergence 2022
Impaired Dynamic X-Chromosome Inactivation Maintenance in T Lymphocytes Is a Feature of Spontaneous Lupus in Female Mice and Is Exacerbated in Female-Biased Disease Models
Nikhil Jiwrajka¹, Natalie Toothacre², Zachary Beethem², Sarah Sting², Katherine Forsyth², Amanda Driscoll², William Stohl³ and Montserrat Anguera², ¹Division of Rheumatology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, ³University of Southern California, Los Angeles, CA
Background/Purpose: SLE is highly female-biased, yet the molecular origins of this bias remain unclear. The X chromosome contains many immune-related genes, suggesting that X-linked epigenetic…
Abstract Number: 2056 • ACR Convergence 2022
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Takehiro Nakai¹, Sho Fukui², Takahiro Asano³, Futoshi Iwata⁴, Hiroki Ozawa⁵, Satoshi Kawaai⁴, Yukihiko Ikeda¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁶, Kenichi YAMAGUCHI⁷ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Kyorin University Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo City Tokyo, Japan, ⁴St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
Abstract Number: 2074 • ACR Convergence 2022
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
Tala El Tal¹, Santiago Arciniegas², Sarah Mossad³, Ibrahim Mohamed⁴, Victoria Lishak⁵, Stephanie Fevrier⁶, Lawrence Ng³, Paris Moaf³, Joanna Law³, ashley Danguecan³, Linda Hiraki⁷, Deborah Levy⁸ and Andrea Knight¹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, ⁵The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁶The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), particularly executive dysfunction (ED), with adverse effects on treatment adherence,…
Abstract Number: 2092 • ACR Convergence 2022
Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
Avira Som¹, Lily McMorrow¹, Ling Chen¹, Deepali Sen¹, Alia El-Qunni¹, Elizabeth Baker² and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Saint Louis University College for Public Health and Social Justice, St. Louis, MO
Background/Purpose: Patients with SLE experience substantial health disparities. Studying the effect of spatial context on health outcomes has become a focus in health disparities research.…
Abstract Number: 2191 • ACR Convergence 2022
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
In Ah Choi¹, Ji Hyoun Kim², Sung Hae Chang³, Hyun Jung Kim⁴ and Hyeong Sik Ahn⁴, ¹Chungbuk National University, Cheongju, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ⁴Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
Abstract Number: 0103 • ACR Convergence 2022
Retention in Rheumatology Care and Receipt of Lupus-Specific Serologic Testing Among Young Adults with Systemic Lupus Erythematosus: A Medicare Cohort Study
Maria Schletzbaum¹, W. Ryan Powell², Shivani Garg³, Joseph A. Kramer⁴, Brad C. Astor⁵, Andrea Gilmore-Bykovskyi⁶, Amy J. Kind⁷ and Christie Bartels⁸, ¹University of Wisconsin School of Medicine and Public Health, Department of Population Health Sciences, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, ³University of Madison, School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Department of Medicine & Center for Health Disparities Research,, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Department of Medicine, Nephrology Division and Department of Population Sciences, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: SLE is a leading cause of mortality in young adults, particularly in those identifying as Black or Hispanic or who are socioeconomically disadvantaged. These…
Abstract Number: 0321 • ACR Convergence 2022
M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort
Eugene Krustev¹, John Hanly², Ricky Chin³, Katherine Buhler¹, Francesca S Cardwell⁴, Murray Urowitz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul R Fortin¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat İnanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Jill Buyon³⁵, Marvin Fritzler¹, Ann E Clarke³⁶ and May Choi³⁷, ¹University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ³University of Calgary, Ottawa, ON, Canada, ⁴University of Waterloo, Department of Geography & Environmental Management, Burlington, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, Republic of Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁹Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²University College London, London, United Kingdom, ¹³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁰University of California San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Charleston, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵NYU Grossman School of Medicine, New York, NY, ³⁶University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ³⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: We previously reported in a single centre prevalent SLE cohort that antibodies against the cytokinesis-associated protein M-Phase Phosphoprotein 1 (anti-MPP-1) were associated with SLE-related…
Abstract Number: 0339 • ACR Convergence 2022
Corneal Confocal Microscopy: A Potential Ophthalmic Imaging Biomarker of Neurodegeneration for Systemic Lupus Erythematosus
Miral H.Gharib¹, Georgios Baloglu², Soha Osman¹, Rayaz A.Malik³ and Samar Al emadi¹, ¹Hamad Medical Corporation, Doha, Qatar, ²Weill Cornell Medicine-Qatar, Research division, Qatar foundation, Doha, Qatar, ³Weill Cornell Medicine-Qatar, Research division, Qatar foundation, institute of cardiovascular sciences, Cardiac center, university of Manchester and NIHR clinical research facility, Doha, Qatar
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease with frequent neuropsychiatric symptoms occurring in 80% to 90% of patients with SLE divided…
Abstract Number: 0360 • ACR Convergence 2022
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Mark Lazarus¹, Paul Newcombe¹, Richard A. Furie², Philip Brohawn³, Wendy White³, Dominic Sinibaldi³, Nicola Ferrari¹, Raj Tummala³, Hussein Al-Mossawi¹, Edward Vital⁴, Eric F. Morand⁵, Daniel Muthas⁶ and Madhu Ramaswamy³, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³AstraZeneca, Gaithersburg, MD, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Monash University, Melbourne, Australia, ⁶AstraZeneca, Gothenburg, Sweden
Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].